AAA formation was decreased in AAV-sh-FoxO3a-treated mice compared with AAV-GFP-treated mice (12 of 30 mice (40%) in the sh-FoxO3a group developed AAAs; 20 of 30 mice (66.7%) in the AAV-GFP group developed AAAs; p < 0.05; Fig. 5 A, B). The gene discussed is FOXO3; the disease is achalasia-alacrima syndrome.